SCHEMBL16617642

SCHEMBL16617642

C[C](C)c1ccc2[nH]ccc2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.68
CYP3A4 P08684 1/20 0.68
MAPT P10636 1/20 0.68
CYP2C19 P33261 1/20 0.68
RAB9A P51151 1/20 0.68
F2 P00734 1/20 0.61
USP2 O75604 1/20 0.55
GAA P10253 1/20 0.55
ALOX15 P16050 1/20 0.55
RAD51 Q06609 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
CTNNB1 P35222 3/20 0.51
WNT3A P56704 3/20 0.51
AHR P35869 3/20 0.50
NR4A2 P43354 2/20 0.50
CYP2A6 P11509 2/20 0.50
F7 P08709 1/20 0.50
LTA4H P09960 1/20 0.50
F3 P13726 1/20 0.50
TUBB4A P04350 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26037653 0.84 CYP1A2 (0.64) CYP1A2CYP3A4MAPTCYP2C19RAB9A
SCHEMBL120471 0.84 MAOA (0.66) CYP1A2CYP3A4MAPTCYP2C19RAB9A
SCHEMBL27804745 0.81 F2 (0.64) CYP1A2CYP3A4MAPTCYP2C19RAB9A
SCHEMBL8817473 0.80 CYP1A2 (0.54) CYP1A2CYP3A4MAPTCYP2C19RAB9A
SCHEMBL27594531 0.79 TUBB4A (0.67) CYP1A2CYP3A4MAPTCYP2C19RAB9A
SCHEMBL23734343 0.78 F2 (0.60) CYP1A2CYP3A4MAPTCYP2C19RAB9A
SCHEMBL24786952 0.78 CYP1A2 (0.57) CYP1A2CYP3A4MAPTCYP2C19RAB9A
SCHEMBL105928 0.78 KDM4E (0.72) CYP1A2CYP3A4MAPTCYP2C19RAB9A
SCHEMBL6447473 0.78 F2 (0.59) CYP1A2CYP3A4MAPTCYP2C19RAB9A
SCHEMBL27664194 0.78 F2 (0.59) CYP1A2CYP3A4MAPTCYP2C19RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180327401-A1 IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER JANSSEN PHARMACEUTICA NV (BE) 2018-11-15 US disclosed
US-10077261-B2 Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer JANSSEN PHARMACEUTICA NV (BE) 2018-09-18 US disclosed
US-20160002219-A1 IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER JANSSEN PHARMACEUTICA NV (BE) 2016-01-07 US disclosed
US-20150099730-A1 IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER JANSSEN PHARMACEUTICA, NV (BE) 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099730-A1 IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER FASN, PLIN1, FABP1 CYP1A2 439/4885CYP3A4 899/4885MAPT 4730/4885
US-10077261-B2 Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer FASN, PLIN1, FABP1 CYP1A2 439/4885CYP3A4 899/4885MAPT 4730/4885
US-20180327401-A1 IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER FASN, PLIN1, FABP1 CYP1A2 439/4885CYP3A4 899/4885MAPT 4730/4885
US-20160002219-A1 IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER FASN, PLIN1, FABP1 CYP1A2 439/4885CYP3A4 899/4885MAPT 4730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.